These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31346639)

  • 1. [Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].
    Harger A; Stemmer K; Tschöp MH; Müller TD
    Internist (Berl); 2019 Sep; 60(9):895-902. PubMed ID: 31346639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut hormone polyagonists for the treatment of type 2 diabetes.
    Brandt SJ; Götz A; Tschöp MH; Müller TD
    Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incretin/glucagon system as a target for pharmacotherapy of obesity.
    Del Prato S; Gallwitz B; Holst JJ; Meier JJ
    Obes Rev; 2022 Feb; 23(2):e13372. PubMed ID: 34713962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
    Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
    Capozzi ME; DiMarchi RD; Tschöp MH; Finan B; Campbell JE
    Endocr Rev; 2018 Oct; 39(5):719-738. PubMed ID: 29905825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
    Gault VA
    Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity pharmacotherapy: incretin action in the central nervous system.
    Boer GA; Hay DL; Tups A
    Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
    Knerr PJ; Mowery SA; Finan B; Perez-Tilve D; Tschöp MH; DiMarchi RD
    Peptides; 2020 Mar; 125():170225. PubMed ID: 31786282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GIP analogues and the treatment of obesity-diabetes.
    Bailey CJ
    Peptides; 2020 Mar; 125():170202. PubMed ID: 31756366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
    Stensen S; Krogh LL; Sparre-Ulrich AH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Gasbjerg LS; Knop FK
    Diabetes Obes Metab; 2022 Sep; 24(9):1882-1887. PubMed ID: 35491518
    [No Abstract]   [Full Text] [Related]  

  • 20. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.